Results 61 to 70 of about 3,690 (153)

Fimsbactin Siderophores From a South African Marine Sponge Symbiont, Marinomonas sp. PE14‐40

Microbial Biotechnology, Volume 18, Issue 5, May 2025.
This work provides evidence of a never‐been‐reported Marinomonas species fimsbactin biosynthesis pathway which produces both the N1‐acetyl‐N1‐hydroxyputrescine‐ and new N1‐acetyl‐N1‐hydroxycadaverine‐containing siderophore structure analogues, an uncommon phenomenon in known fimsbactin producers. This study also discusses the role of enzyme promiscuity
Nompumelelo Philile Praiseworth Ikegwuoha, Thea Hanekom, Elzaan Booysen, Corbyn Jason, Shirley Parker‐Nance, Michael T. Davies‐Coleman, Leonardo Joaquim van Zyl, Marla Trindade   +7 more
wiley   +1 more source

Spotlight commentary: Treatment of multidrug‐resistant Gram‐negative infections in the era of growing antimicrobial resistance

British Journal of Clinical Pharmacology, Volume 91, Issue 9, Page 2485-2489, September 2025.
Luka Bielen, Andro Vujević, Luka Csenar
wiley   +1 more source

The Efficacy of Topical Cefiderocol Treatment of Experimental Extensively Drug-Resistant Pseudomonas aeruginosa Keratitis Is Dependent upon the State of the Corneal Epithelium

Antibiotics
Background: An overlooked factor in the efficacy of topical antibiotics to treat bacterial keratitis is the state of the corneal epithelium. Recently, we evaluated topical cefiderocol for the treatment of extensively drug-resistant (XDR) Pseudomonas ...
Eric G. Romanowski, Jonathan B. Mandell, Vishal Jhanji, Robert M.Q. Shanks   +3 more
doaj   +1 more source

Treatment of Carbapenem-Resistant Acinetobacter baumannii in Real Life (T-ACI): A Prospective Single-Center Observational Study

Antibiotics
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) poses significant challenges in healthcare due to its multidrug resistance and high mortality rates among critically ill patients. Results: We enrolled 45 patients.
Antonio Riccardo Buonomo, Riccardo Scotto, Nunzia Esposito, Giulio Viceconte, Nicola Schiano Moriello, Giulia Zumbo, Ilaria Vecchietti, Amedeo Lanzardo, Carmine Iacovazzo, Francesco Curcio, Emanuela Roscetto, Ivan Gentile   +11 more
doaj   +1 more source

When the Trojan horse is unable to reach inside the city: investigation of the mechanism of resistance behind the first reported cefiderocol-resistant E. coli in Canada

Microbiology Spectrum
Gram-negative metallo-β-lactamase-producing bacteria can be extremely problematic, especially when found to be extensively drug-resistant (XDR). Cefiderocol is a novel antimicrobial that has been shown to overcome most carbapenemases, with very rare ...
Kevin R. Barker, Gabriel W. Rebick, Ken Fakharuddin, Clayton MacDonald, Michael R. Mulvey, Laura F. Mataseje   +5 more
doaj   +1 more source

Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study

Infectious Diseases and Therapy
Introduction Cefiderocol is a siderophore cephalosporin showing activity against various carbapenem-resistant Gram-negative bacteria (CR-GNB). No data currently exist about real-world use of cefiderocol in terms of types of therapy (e.g., empirical or ...
Daniele Roberto Giacobbe, Laura Labate, Chiara Russo Artimagnella, Cristina Marelli, Alessio Signori, Vincenzo Di Pilato, Chiara Aldieri, Alessandra Bandera, Federica Briano, Bruno Cacopardo, Alessandra Calabresi, Federico Capra Marzani, Anna Carretta, Annamaria Cattelan, Luca Ceccarelli, Giovanni Cenderello, Silvia Corcione, Andrea Cortegiani, Rosario Cultrera, Francesco Giuseppe De Rosa, Valerio Del Bono, Filippo Del Puente, Chiara Fanelli, Fiorenza Fava, Daniela Francisci, Nicholas Geremia, Lucia Graziani, Andrea Lombardi, Angela Raffaella Losito, Ivana Maida, Andrea Marino, Maria Mazzitelli, Marco Merli, Roberta Monardo, Alessandra Mularoni, Chiara Oltolini, Carlo Pallotto, Emanuele Pontali, Francesca Raffaelli, Matteo Rinaldi, Marco Ripa, Teresa Antonia Santantonio, Francesco Saverio Serino, Michele Spinicci, Carlo Torti, Enrico Maria Trecarichi, Mario Tumbarello, Malgorzata Mikulska, Mauro Giacomini, Anna Marchese, Antonio Vena, Matteo Bassetti, CEFI-SITA investigators   +52 more
doaj   +1 more source

Emergence of cefiderocol resistance during therapy in NDM-5–producing Klebsiella pneumoniae isolates harboring siderophore receptors mutations

International Journal of Infectious Diseases
Cefiderocol, a siderophore-conjugated cephalosporine, is a promising drug used to treat infection with carbapenem-resistant gram-negative bacteria. Here, we report a case of pneumonia induced by multiple gram-negative pathogens, including a carbapenem ...
Luc Deroche, Albane Rozenholc, François Arrivé, Jean-Philippe Martellosio, Gwenaël Le Moal, Arnaud W. Thille, Olivier Barraud, Sandrine Marchand, Julien M. Buyck   +8 more
doaj   +1 more source

Addressing antimicrobial resistance: Structural insights into cefiderocol’s mode of action and emerging resistance mechanisms

Journal of Infection and Public Health
Cefiderocol represents a significant advancement in the treatment of multidrug-resistant Gram-negative bacterial infections. Its unique uptake mechanism, leveraging bacterial iron transport pathways for membrane permeation, sets it apart from ...
Mohd Zulkifli Salleh
doaj   +1 more source

In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis

Journal of Global Antimicrobial Resistance
: Objectives: Gram-negative pathogens causing respiratory infection in people with cystic fibrosis and bronchiectasis are becoming progressively more resistant to conventional antibiotics. Although cefiderocol is licenced for the treatment of infections
Michael M Tunney, J Stuart Elborn, Chloe S McLaughlin, Christopher M Longshaw   +3 more
doaj   +1 more source

Exploring mutational possibilities of KPC variants to reach high level resistance to cefiderocol

Scientific Reports
Klebsiella pneumoniae carbapenemase (KPC) is a frequent and widespread carbapenemase, with over 260 variants identified. While KPC often evolves resistance to ceftazidime-avibactam, cefiderocol remains a key treatment option.
Sidonie Hanna, Kevin La, Yutaka Yoshii, Maud Gits-Muselli, Imane El Meouche, Yasmine Benhadid-brahmi, Stéphane Bonacorsi, André Birgy   +7 more
doaj   +1 more source